Hereditary factor in early prostate cancer:
This article was originally published in Clinica
Prostate cancer has a strong familial factor affecting younger patients. Familial prostate cancer is transmitted in an autosomal dominant manner, says a review in the Canadian Medical Association Journal (Vol. 153, pp 895-900). The familial condition accounts for 43% of cases in men under 55 years, but only 9% of prostate cancer cases overall.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.